UBS raised the firm’s price target on Amgen (AMGN) to $319 from $315 and keeps a Neutral rating on the shares. The firm is expecting an in-line quarter, adding in a preview that it will be on watch for key commentaries around tariffs and taxes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Sandoz files antitrust litigation against Amgen regarding Enbrel
- Amgen says Phase 3 DeLLphi-304 trial of Imdelltra met primary endpoint
- Quantum Computing News: Quantum Firms Drive New Breakthroughs in 2025
- Morning Movers: Pharmaceuticals sink as impending tariffs seen coming
- Amgen price target raised to $330 from $328 at Morgan Stanley